The principal objective of the study is the evaluation of the role of Human Papilloma Virus (HPV) in plantar warts (prevalence, genotype), resistant or not, treated or not, cured or not. This epidemiological study is an ancillary study of the prospective, randomized controlled, clinical study VRAIE (sponsor: APHP) comparing 5 usual strategies in the management of plantar warts.
Study Type
OBSERVATIONAL
Enrollment
406
viral status assessment of skin flakes
Detection of HPV viral DNA on samples
research of positive HPV status
Time frame: up to Day 90
Distribution of viral genotypes
number of samples containing one or more viral type (type 1, 2, 4 or mix)
Time frame: up to Day 90
Clinical remission defined
complete remission of wards confirmed by the physician, no later than day 90
Time frame: up to Day 90
Viral remission for patients with wards resistant to treatments
viral status modification from negative to positive between day 0 and day 30, day 60 or no more than day 90.
Time frame: up to Day 90
Clinical relapse
Time frame: 21 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.